Apr. 12 2024
Source Page: Non-technical summaries granted in 2024Found: Furthe r, the behavioural and physiological studies use minimally invasive procedures, that are
Mar. 14 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023Found: cancer (2), m etastati c cancer (1), to nsil cancer (1), ovarian cancer (1), pancreatic cancer (1),
Jan. 31 2024
Source Page: Progressive Stroke Pathway remit and purpose: FOI releaseFound: INR: Interventional Neuroradiologist s: doctors who specialise in minimally invasive treatment of
Jan. 17 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 17 October 2022Found: ......................................................................................... 54 5.4.7 Cancer
Asked by: Lord Browne of Belmont (Democratic Unionist Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what measures they are taking to increase the availability of non-invasive cancer treatment technologies.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service continues to increase investment in minimally invasive cancer therapies, radiotherapy, and chemotherapy services. Since April 2022, the responsibility for investing in new radiotherapy machines has sat with local systems. This is supported by the 2021 Spending Review, which set aside £12 billion in operational capital for the NHS from 2022 to 2025.
The adoption of new treatments, including increasing the number of minimally invasive cancer treatments and technologies, into the NHS in England is generally the result of National Institution of Clinical Excellence (NICE) guidance and commissioner decisions. Both NHS England and integrated care boards are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by NICE.
Where treatments are approved by NICE through the Technology Appraisals programme, the National Health Service is required to make them available within agreed timescales, which vary by technology. Implementation of any NICE approvals will be supported by the service readiness assessment and the development of additional capacity where necessary.
NHS England’s Specialised Commissioning team has been undertaking work to expand the number of providers offering minimally invasive cancer therapies, such as selective internal radiation therapy. The market engagement and Prior Information Notice aspects of this have now been completed, with regional teams now putting in place the necessary contractual arrangements with NHS trusts.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase awareness of minimally invasive cancer therapies among (a) healthcare professionals and (b) patients.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department recognises that for some cancer patients, minimally invasive cancer therapies have the potential to improve recovery, reduce the length of bed stays in hospital, and produce fewer side effects from treatment. However, cancer patients will often have a range of treatment choices available to them. It is important that informed decisions are taken by each patient, in consultation with their treating clinician, following the advice of multi-disciplinary teams that are expert in the management of cancer. Promotion of one approach would not be appropriate for each patient, so awareness campaigns are not normally undertaken by the Department and the National Health Service.
The adoption of new treatments, including minimally invasive cancer treatments, into the NHS in England is generally the result of National Institute for Health and Care Excellence (NICE) guidance and/or commissioner decisions. This guidance is available at the following link:
https://www.nice.org.uk/guidance/published
For treatments that form part of a prescribed specialised or highly specialised service, NHS England’s specialised commissioning function is responsible for putting in place access. For treatments that are not part of a prescribed specialised service, the responsibility sits with integrated care boards (ICBs). Both NHS England and ICBs are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by NICE. Pharmaceutical companies are also able to accelerate access to new treatments and technologies through schemes like the Early Access to Medicines Scheme, Project Orbis or The Innovative Licensing and Access Pathway, enabling patients to benefit from innovative treatments quickly.
Looking ahead, from April 2024, ICBs will become the responsible commissioner for several specialised services and will want to work with and through local Cancer Alliances to plan and organise access to care for their populations that meets national standards. By integrating the commissioning of specialised and non-specialised services, ICBs will be able to join-up care around patient needs and invest resources where they can have best effect on outcomes, including any decisions on minimally invasive cancer therapies.
Nov. 28 2023
Source Page: Clinical Impact Awards 2022: personal statementsFound: I have achieved this by introducing advanced diagnostics, transitioning to minimally invasive robotic
Asked by: Kim Johnson (Labour - Liverpool, Riverside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase public awareness of minimally invasive cancer therapies.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department and NHS do not normally undertake public awareness campaigns on treatments and therapies. This is because cancer patients will often have a range of treatment choices available to them and it is important that informed decisions are taken by each patient, in consultation with their treating clinician, following the advice of multi-disciplinary teams that are experts in the management of cancer.
Instead, the Department and the NHS’s focus is on early diagnosis, including raising awareness of cancer symptoms and encouraging people to come forward through public awareness campaigns such as ‘Help us, help you’. By encouraging earlier diagnosis, cancer patients will have a wider range of treatment options available to consider, including minimally invasive therapies where appropriate.
The adoption of new treatments, including minimally invasive cancer treatments, into the NHS in England is generally the result of National Institute for Health and Care Excellence (NICE) guidance and/or commissioner decisions. For treatments that form part of a prescribed specialised or highly specialised service, NHS England’s specialised commissioning function is responsible for putting in place access. For treatments that are not part of a prescribed specialised service, the responsibility sits with integrated care boards (ICBs). Both NHS England and ICBs are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by NICE. Pharmaceutical companies are also able to accelerate access to new treatments and technologies through schemes like the Early Access to Medicines Scheme, Project Orbis or The Innovative Licensing and Access Pathway, enabling patients to benefit from innovative treatments quickly.
Looking ahead, from April 2024, ICBs will become the responsible commissioner for a number of specialised services and will want to work with and through local Cancer Alliances to plan and organise access to care that meets national standards. By integrating the commissioning of specialised and non-specialised services, ICBs will be able to join-up care around patient needs and invest in resources where they can have best effect on outcomes.
Mentions:
1: Lord Markham (Con - Life peer) This will save thousands of lives and prevent thousands more people suffering from cancer. - Speech Link
2: Lord Bishop of London (Bshp - Bishops) The General Synod of the Church of England voted to call on the Government to ban conversion therapies - Speech Link
3: Baroness Walmsley (LD - Life peer) cancer, et cetera, but what is needed is widespread access to treatment. - Speech Link
4: Lord Lexden (Con - Life peer) Drug therapies can reduce the rates of refracture by up to 90% for the most common fractures.Both business - Speech Link
Mentions:
1: Will Quince (Con - Colchester) that we are getting it right as we develop the strategy.I would also like to touch on gene and cell therapies - Speech Link